Tyler Flores

SOLAI shareholders approved a massive 30 billion share increase, arming the firm for a radical pivot into AI and the Solana ecosystem. But what about dilution?

Former CEO Phil Horlock's full departure marks a new chapter for Blue Bird, which is posting record profits and accelerating its lead in electric buses.

XA Investments is launching a new index for credit interval funds, a move set to demystify a booming but opaque market for investors and asset managers.

A new device is bringing live streaming and video calls to the deep. DIVEVOLK's SeaLink is nominated for a top innovation award for changing the game.

Beyond tracking, a new AI mattress from Stareep promises to actively intervene and optimize your sleep. But is it a true revolution in a crowded market?

Danish water tech firm Aquaporin seeks urgent funding, warning of 77% dilution for shareholders as it races to secure its future and new technology.

The VCT posts a marginal loss but shows second-half recovery, while navigating strategic exits and facing a pivotal shift in UK VCT tax policy.

A new report reveals a shocking decline in Canadian public companies and IPOs, signaling economic stagnation and shutting out average investors.

Bitwarden launches real-time vault alerts and password coaching, moving beyond simple warnings to actively guide users in securing their digital lives.

New partnership launches TileDB Carrara on Snowflake, aiming to shatter data silos and accelerate breakthroughs in healthcare and life sciences.

Tebra's new $250M funding aims to level the playing field for private practices with AI tools that automate tasks and boost profitability.

From crypto pivots to robotics rallies, companies are making bold moves. But as narratives shift, discerning hype from reality is more crucial than ever.

A new partnership in Northeast Ohio allows health plan members to buy nutritious groceries with a simple card swipe, turning local stores into health hubs.

When a superstorm threatened a 10,000-person conference, one firm's crisis response offered a masterclass in resilience with lessons for the entire industry.

A pivotal trial success in lupus for BTK inhibitor orelabrutinib not only offers new hope for patients but also validates Zenas BioPharma's strategy.

Two Bay Area event firms gain a key certification, strategically positioning them to tap into the lucrative healthcare conference market via supplier diversity.

A C$1M private placement for CHAR Technologies signals strong investor faith in its waste-to-energy tech, promising to decarbonize heavy industry.

PSH continues its multi-billion dollar share repurchase strategy to tackle its stubborn stock discount. What does this mean for the fund and its future targets?

New AI voice agents promise to capture millions in lost revenue for med spas by working after hours. Is this the future of the aesthetic care market?

The private capital market leader's latest user-voted award reveals a major trend: authentic customer feedback is the new currency in high-stakes investing.